Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: Olivia M. Merkel Clear advanced filters

  • Merkel cell carcinoma (MCC) is a rare aggressive skin cancer with limited therapeutic options. In this work, the authors identify aurora kinase B (AURKB) as a critical therapeutic target for MCC, supported by tumour shrinkage and increased survival when using the AURKB inhibitor AZD2811 nanoparticle formulation in MCC preclinical models.

    • Tara Gelb
    • Khalid A. Garman
    • Isaac Brownell
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-15

  • T cells can recognise lipid antigen in the context of CD1d molecules. Here, the authors show that γδ T cell activation in response to CD1d differs from that of αβ T cells and determine the structure of a γδ T cell receptor that binds to CD1d independently of the presented lipid.

    • Michael T. Rice
    • Sachith D. Gunasinghe
    • Jamie Rossjohn
    ResearchOpen Access
    Nature Communications
    Volume: 17, P: 1-12

  • In an analysis of long-term safety events in 783 patients treated with T cell therapy in 38 trials, 2.3% of patients developed second primary malignancies, and vector integration analyses revealed no pathological insertions.

    • Julie K. Jadlowsky
    • Elizabeth O. Hexner
    • Joseph A. Fraietta
    Research
    Nature Medicine
    Volume: 31, P: 1134-1144

  • Efficient and targeted delivery of nucleic acids is critical for realizing the full therapeutic potential of gene editing, vaccines and RNA-based drugs, and emerging delivery platforms offer innovative solutions through their diverse architectures, tunable properties and distinct biological interactions. In this Viewpoint, researchers working across different delivery platforms — including lipid nanoparticles, synthetic polymers, peptide amphiphiles, coacervate microdroplets, DNA nanostructures and extracellular vesicles — discuss the most promising directions and the main challenges in shaping the future of nucleic acid delivery.

    • Roy van der Meel
    • Paul A. Wender
    • Paola Luciani
    Reviews
    Nature Reviews Materials
    Volume: 10, P: 490-499